S457
Clinical - Gynaecological
ESTRO 2026
Results: 193 out of 240 PARCER patients with at least 12 months of follow-up were analyzed. Figure1 shows AEs/symptoms contributing to CTSCTCAE and CTSEORTC and the score distributions, revealing significant differences between treatment arms (p=0.004and p=0.017 respectively). Figure 2 illustrates the relationship between CTS and global- QOL. CTSEORTC distributions differed significantly for each pair wise comparison of global-QOL levels. CTSCTCAE showed significant pair wise differences for large and medium global-QOL deteriorations versus reference (p <0.001 and p = 0.004), but not for small deteriorations versus reference or between large vs medium deteriorations. Conclusion: The applicability of the cumulative toxicity score in a randomized phase-III trial was demonstrated, and the first comprehensive analysis of PARCER symptoms/AEs is reported. The CTS identified significant differences between treatment arms by integrating organ-related and general morbidity, confirming strong correlations with global- QOL (not shown in the original study). Patient-reported outcomes detected larger differences between both treatment arms and global-QOL levels. References: 1) Pelizzola, M., et al.(2025) 2832 Engaging patients’ experience in a cumulative toxicity score as endpoint for clinical trials: an example from cervical cancer. Radiother Oncol2) Pötter, R., et al.(2021) MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol3) Chopra, S., et al.(2021) Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial. J Clin Oncol4) Cocks, K., et al.(2012) Evidence-based
guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. EJC Keywords: patient reported outcome, cumulative toxicity score
Digital Poster 2782 Longitudinal health-related quality of life
trends in rare and radioresistant gynaecological cancer patients undergoing hadrontherapy
Amelia Barcellini 1,2 , Alessandro Vai 3 , Carmine Tinelli 4 , Elisa De Carlo 5 , Chiara Canonaco 5 , Chiara Cassani 6,7 , Nadia Facchinetti 8 , Jessica Franzetti 2 , Concetta Laliscia 9 , Fabio Landoni 10 , Laura Deborah Locati 1,11 , Giuseppe Magro 3 , Giorgia Mangili 12 , Fabio Martinelli 10,13 , Federica Piccolo 14 , Paola Valla 2 , Viviana Vitolo 2 , Rossella E Nappi 6,15 , Ester Orlandi 6,2 1 Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. 2 Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. 3 Medical Physics Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. 4 Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. 5 Medical School, University of Pavia, Pavia, Italy. 6 Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy. 7 Unit of Obstetrics and Gynecology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 8 Clinical Trials Center, Scientific Directionship, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy. 9 Department of Translational Medicine, Radiation Oncology Division, University of Pisa, Pisa, Italy. 10 Department of Gynecologic Oncology, Humanitas San Pio X, Milano, Italy. 11 Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy. 12 Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy.
Made with FlippingBook - Share PDF online